Navigation Links
Mutated Suppressor Gene Leads to a Type of Breast Cancer
Date:12/10/2007

Finding could lead to new treatments, researchers say

MONDAY, Dec. 10 (HealthDay News) -- Scientists believe they've discovered how mutations in the cancer-susceptibility gene called BRCA1 can cause some breast cancers.

Basal-like breast cancers (BBCs) represent 10 percent to 20 percent of all breast cancers. BBCs generally have a poor prognosis, are difficult to treat, and are almost always associated with hereditary mutations in the BRCA1 gene, the researchers said.

The researchers found that inherited mutations in the BRCA1 gene deactivate another gene known as PTEN, which helps to suppress tumors. This suppressor gene is deactivated by the mutated BRCA1 gene's failure to repair a break in the PTEN gene's DNA, the scientists said.

The loss of the PTEN gene's tumor-suppressing ability allows increased cell activity that increases tumor growth. That action "can convert the cell from being a well-behaving entity to a bad citizen," said study co-author Dr. Ramon Parsons, a professor of medicine and pathology at Columbia University's College of Physicians and Surgeons.

"This is a very important finding, because this type of breast cancer doesn't have a type of therapy targeted at this point," Parsons said. Basal-like or triple negative tumors don't have receptors for the hormones estrogen and progesterone or the protein HER2, which most breast cancer therapies target, he said. Drugs that can target the pathway related to mutated PTEN genes "may be a way we can improve the survival for women with these basal-like tumors," he added.

Parsons said several pharmaceutical companies already are developing drugs to do just that.

"My guess is there's going to be a huge bolus of clinical trials with these drugs in the next couple of years," he said. "Since there's going to be such a large variety of compounds, my hunch is one or more will be effective." By effective, Parson said he doesn't mean one of them will offer a cure, but the drugs in the right combination could lead to a cure.

The development of these drugs also may be important for other types of cancers that can involve deactivating the PTEN gene, Parsons said.

The study results were published online Dec. 9 in the journal Nature Genetics.

Parsons said the discovery of the PTEN deactivation "was kind of a real long-term detective story." For 10 years, researchers have been trying to understand how the mutation in the BRCA1 gene can cause breast cancer. Instead of using traditional gene-sequencing techniques, Parsons and his colleagues looked for physical breaks in the PTEN gene. "PTEN is actually physically broken in half, we estimate, in 30 to more than 50 percent of the BRCA1 tumors," he said.

Dr. Jeffrey Weitzel, an associate professor of medical oncology at the City of Hope Comprehensive Cancer Center in Duarte, Calif., said the study by Parsons' team "helps us understand what's under-appreciated in the complex nature of tumor changes."

Andrew Godwin, director of the clinical molecular genetics laboratory at the Fox Chase Cancer Center in Philadelphia, added: "As we move towards personalized health care [and] medicine, identifying the cadre of genetic defects in a given breast tumor will likely influence how that patient is ultimately treated."

More information

For more on breast cancer, visit the U.S. National Cancer Institute.



SOURCES: Andrew Godwin, Ph.D., director, Clinical Molecular Genetics Laboratory and the Biosample Repository, Fox Chase Cancer Center, Philadelphia; Ramon Parsons, M.D., Ph.D., director of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center of Columbia University Medical Center and New York-Presbyterian Hospital, and professor of medicine and pathology, Columbia University College of Physicians and Surgeons, New York City; Jeffrey Weitzel, M.D., associate professor of medical oncology, director, department of clinical cancer genetics, City of Hope Comprehensive Cancer Center, Duarte, Calif.; Dec. 9, 2007, Nature Genetics, online


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study details regulation of vital tumor suppressor gene p53
2. M. D. Anderson researchers identify tumor-suppressor gene for lung cancer
3. Removing Ovaries Before Menopause Leads to Memory, Movement Troubles
4. Lack of sleep among new school-goers leads to behavioral, cognitive problems
5. Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations
6. AstraZeneca Leads Local Walking Movement
7. Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health
8. Support System Leads to Better Diet, Nutrition
9. Brain atrophy in elderly leads to unintended racism, depression and problem gambling
10. Medical University of South Carolina Leads Multicenter Study Evaluating Biliary Sphincter Disorder
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mutated Suppressor Gene Leads to a Type of Breast Cancer
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office accelerates and supports FNCC’s ... added 10 new sales professionals over the past 6 months and is continuing to ... hires over the course of 2017. , “This new office is a direct ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. ... launch of a months-long rebranding effort. This includes the introduction of new packaging ... discussions and market research, we learned that a simple, proactive approach to wellness ...
(Date:3/27/2017)... Orange, Texas (PRWEB) , ... March 27, 2017 ... ... celebration at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to ... giveaways and will be an opportunity for area-residents to celebrate two great years ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion ... renovations is also on the rise. Per a 2017 report, 13% of all households ... to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only ...
(Date:3/26/2017)... ... 2017 , ... Local physician Dr. Justin Harper is one ... honoring the top influencers on RealSelf—the most trusted online destination to get informed ... , In 2016, more than 82 million people visited RealSelf to research cosmetic ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)...  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company ... in children, today reported financial results for the ... 2016 and provided an update on its corporate ... progress during the fourth quarter of 2016 through ... safety study, and with our lead development candidate, ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets ... Market, 2017-2027" report to their offering. ... The Cell Therapy Manufacturing ... growing market of cell therapy manufacturing and focuses both on ... These therapies are anticipated to emerge as viable alternatives to ...
(Date:3/24/2017)... March 24, 2017  Zymo Research Corp., ... Hamilton Robotics, Inc., who designs, manufactures and ... collaboration that teams Zymo Research,s DNA methylation ... DNA extraction products with Hamilton,s high-throughput automation ... methods for microbiomics and RNA isolation for ...
Breaking Medicine Technology: